Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group

Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy

(2013) Rohit Loomba et al.   ANNALS OF INTERNAL MEDICINE

Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma

(2013) Y. Oki et al.   CLINICAL CANCER RESEARCH

Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study

(2013) Emanuele Zucca et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases

(2012) Carlos Montalbán et al.   BRITISH JOURNAL OF HAEMATOLOGY

Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice

(2012) Christiane Copie-Bergman et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)

(2012) B. Kiesewetter et al.   HAEMATOLOGICA

Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie

(2012) M. Troch et al.   HAEMATOLOGICA

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

(2012) C. Renner et al.   HAEMATOLOGICA

Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin’s Lymphoma: Results, Biology, and Development Strategies

(2011) Jonathan H. Schatz   Current Oncology Reports

Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)

(2010) A. Conconi et al.   ANNALS OF ONCOLOGY

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

(2010) A. Rinaldi et al.   BLOOD

Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia

(2010) Irene M. Ghobrial et al.   JOURNAL OF CLINICAL ONCOLOGY

Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium

(2010) Sonali M. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

(2010) T E Witzig et al.   LEUKEMIA

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

(2009) N. Di Bella et al.   BLOOD

A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas

(2009) Jennifer R. Brown et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Marginal Zone Lymphomas

(2008) Emanuele Zucca et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA